View More Recent Stories
-
Revolution (RVMD) PT Raised to $55 at BofA Securities
-
Revolution (RVMD) PT Raised to $73 at Jefferies
-
Revolution (RVMD) PT Raised to $57 at Stifel
-
Revolution Medicines (RVMD) provides pipeline updates
-
Barclays Starts Revolution (RVMD) at Overweight
-
Revolution Medicines (RVMD) Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
-
Jefferies Starts Revolution (RVMD) at Buy
-
TD Cowen Reiterates Buy Rating on Revolution (RVMD)
